Login to Your Account



Teva Outbids Valeant for Cephalon in $6.8B Cash Offer

By Catherine Shaffer


Wednesday, May 4, 2011
Jerusalem-based Teva Pharmaceutical Industries Ltd. announced Monday that it will acquire Frazer, Pa.-based Cephalon Inc. for $6.8 billion in cash, trumping Valeant Pharmaceutical International Inc.'s recent hostile bid of $5.7 billion.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription